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         Introduction 
Fluoxetine,  (±)–N–methyl–Y–[4–(trifluoromethyl) 
phenoxy] benzene propanamine) (FLX), is a selective 
serotonin reuptake inhibitor in presynaptic neurons. It 
was introduced in 1980s, and since then, it is the most 
prescribed antidepressant drug worldwide. It is used to 
treat  mental  depression,  obsessive–compulsive 
disorder, nervous bulimia, and premenstrual dysphoric 
disorder.
1,2 
Absolute bioavailability of oral FLX in dogs is about 
72% of the intravenous dose. In humans, following a 
single oral dose of 40 mg, peak plasma concentrations 
of FLX were from 15 to 55 ng/mL and observed after 6 
to  8  hours.  FLX  predominantly  undergoes  N–
demethylation  to  norfluoxetine  (NFLX),  which  has 
similar  activity  to  FLX.
3  Both  FLX  and  NFLX  have 
long elimination half–lives, ranging from 1 to 6 days 
and from 5 to 6 days, respectively. About 11% of the 
dose is excreted as unchanged FLX and about 7% as 
NFLX. The therapeutic dose can vary from 20 to 60 mg 
per day depending on the treatment and the urine levels 
excreted are usually at mg/L levels.
3,4 
FLX  has  been  determined  in  its  pharmaceutical 
formulations  by  spectrophotometry,
5–9 
spectrofluorimetry,
9–11  high  performance  liquid 
chromatography  (HPLC),
8,12  gas  chromatography 
(GC),
13  capillary  electrophoresis  (CE),
11,14  nuclear 
magnetic resonance spectrometry
15 and voltammetry.
16 
The  spectrophotometric  methods  are  associated  with 
some major drawbacks such as the lack of sensitivity, 
selectivity,  tedious  extraction  procedures  and  time–
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Purpose: Fluoxetine is the most prescribed antidepressant drug worldwide. In 
this work, a new dispersive liquid–liquid microextraction (DLLME) method 
combined with spectrofluorimetry has been developed for the extraction and 
determination  of  FLX  in  pharmaceutical  formulations  and  human  urine. 
Methods:  For  FLX  determination,  the  pH  of  a  10  mL  of  sample  solution 
containing FLX, was adjusted to 11.0. Then, 800 µL of ethanol containing 100 
µL  of  chloroform  was  injected  rapidly  into  the  sample  solution.  A  cloudy 
solution was formed and FLX extracted into the fine droplets of chloroform. 
After centrifugation,  the  extraction  solvent was  sedimented  and  supernatant 
aqueous phase was readily decanted. The remained organic phase was diluted 
with ethanol and its fluorescence was measured at 292±3 nm after excitation at 
234±3 nm. Results: Some important parameters influencing microextraction 
efficiency were investigated. Under the optimum extraction conditions, a linear 
calibration curve in the range of 10 to 800 ng/mL with a correlation coefficient 
of  r
2  =  0.9993  was  obtained.  Limit  of  detection  (LOD)  and  limit  of 
quantification (LOQ) were found to be 2.78 and 9.28 ng/mL, respectively. The 
relative standard deviations (RSDs) were less than 4%. Average recoveries for 
spiked samples were 93–104%. Conclusion: The proposed method gives a very 
rapid, simple, sensitive, wide dynamic range and low–cost procedure for the 
determination of FLX. 
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consuming.
5-7  Other  methods  were  time  consuming, 
tedious and/or dedicated to sophisticated and expensive 
analytical instruments.
5,9 
On  the  other  hand,  several  methods  have  been 
described for  the  determination  of  FLX  in  biological 
fluids. The most widely used methods involve HPLC 
with  ultraviolet,
3,4,12,17  fluorescence,
18-20  mass 
spectrometry  (MS)
20,21  or  diode  array  detection.
22,23 
FLX levels can also be measured in biological samples 
using  GC,
24  GC–MS
25  and  CE.
2  Liquid–liquid 
extraction  (LLE),
3,4,18,20,21,25  solid  phase  extraction 
(SPE),
2,22,25 and solid phase microextraction (SPME)
23 
are the most common sample preparation techniques to 
analyze  FLX  and  NFLX  in  biological  fluids.  LLE  is 
considered  a  tedious,  time–consuming  procedure, 
which  can  produce  emulsions  and  requires  large 
amounts  of  high  purity  organic  solvents  for  analyte 
extraction. SPE techniques often introduce artifacts into 
the sample extracts and can require lengthy processing 
(i.e.,  washing,  conditioning,  eluting  and  drying).
19 
Thus, there is a need for developing new and efficient 
methods to overcome these drawbacks. 
Recently miniaturized techniques, such as DLLME has 
been developed for sample preparation.
26 It is based on 
a ternary component solvent system like homogeneous 
LLE and cloud point extraction (CPE). In this method, 
the  appropriate  mixture  of  extraction  and  disperser 
solvent  is  injected  into  aqueous  sample  rapidly  by 
syringe, and a cloudy solution is formed. The analyte in 
the  sample  is  extracted  into  the  fine  droplets  of 
extraction solvent. After extraction, phase separation is 
performed by centrifugation and the enriched analyte in 
the  sedimented  phase  is  determined  by  proper 
instrumental method. The ease of the operation, speed, 
lower sample volume, low cost, high recovery and high 
enhancement factor are some advantages of DLLME.
27 
With the development of DLLME, the principles and 
the  applications  of  this  new  technique  have  been 
reviewed  recently
28,29  and  its  application  extended  to 
separation,  preconcentration  and  determination  of 
organic
26,30-33  and  inorganic
27,34-37  compounds  in 
different  samples.  However,  to  the  best  of  our 
knowledge,  this  is  the  first  report  concerning  FLX 
extraction using the DLLME method and second one 
concerning liquid–phase microextraction techniques.  
In this study, DLLME followed by spectrofluorimetry 
has been investigated and optimized for the extraction 
and  determination  of  FLX  in  pharmaceutical 
formulations and human urine. The effects of various 
experimental parameters, such as the kind and volume 
of  extraction  and  dispersive  solvent,  extraction  time, 
sample  solution  pH,  salt  effect,  sample  volume, 
centrifugation  time  and  speed  were  studied  and 
optimized systematically. Using the developed method 
FLX  can  be  analyzed  in  pharmaceutical  formulations 
and human urine in a simpler, cheaper and more rapid 
manner. 
 
Materials and Methods 
Apparatus 
All  fluorescence  measurements  were  made  using  a 
Shimadzu  RF–5301  PC  spectrofluorophotometer 
equipped with a 150 W Xenon lamp and quartz micro–
cell with a path length of 10 mm and a volume of 700 
μL. Instrument excitation and emission slits both were 
adjusted to 5 nm. A centrifuge from Hettich (EBA 20 
model/ Andreas Hettich GmbH & Co. KG, Föhrenstr. 
12,  D–78532  Tuttlingen,  Germany)  with  15  mL 
calibrated centrifuge tubes (Hirschmann, EM techcolor, 
Germany) was used to accelerate the phase separation 
process. The pH–meter model M120 (Halstead, Essex, 
England  CO9  2DX)  supplied  with  a  glass  combined 
electrode was used for the pH measurements. 
 
Reagents 
All  solvents  containing  chloroform,  dichloromethane, 
carbon tetrachloride, acetone, acetonitrile, ethanol and 
methanol  were  obtained  from  Merck  (Darmstadt, 
Germany).  
A stock solution of 1000 μg/mL of FLX was prepared 
by  dissolving  appropriate  amount  of  FLX 
hydrochloride  (obtained  from  Dr.  Abidi  Pharm.  Co., 
Tehran, Iran) in ultrapure water and stored away from 
the light at 4°C. This solution was stable for at least 2 
weeks. Working standard solutions were prepared daily 
by appropriate dilution of this stock standard solution. 
The ammonia buffer (1.0 mol/L, pH 11.0) was prepared 
from  ammonium  chloride  (Merck)  and  ammonia 
(Merck). All chemicals used were of analytical–reagent 
grade or higher. Ultrapure water (Milli–Q Advantage A 
10 system, Millipore) was used throughout the work. 
 
Recommended procedures 
Procedure for DLLME 
The pH of a 10 mL of sample solution, containing FLX 
in the range 10–800 ng/mL, was adjusted to 11.0 with 
1.0 mol/L ammonia buffer and the solution was placed 
in a 10 mL glass test tube with conical bottom. Then, 
800 µL of ethanol (as disperser solvent) containing 100 
µL of chloroform (as extraction solvent) was injected 
rapidly into  the sample  solution by  using a  2.00–mL 
syringe.  A  cloudy  solution  (water,  ethanol,  and 
chloroform) was formed in the test tube. In this step, 
the FLX was extracted into the very fine droplets  of 
chloroform in a few seconds. After centrifugation for 5 
min at 3500 rpm, the extraction solvent was sedimented 
in the bottom of the conical test tube. The supernatant 
aqueous  phase  was  readily  decanted  with  a  Pasteur 
pipette. The remained organic phase was diluted to 1 
mL with ethanol and its fluorescence was measured at 
292±3 nm with the excitation wavelength set at 234 ± 3 
nm. 
 
Procedure for pharmaceutical formulation 
Capsule:  Contents  of  twenty  capsules  (Dr.  Abidi. 
Pharm. Co., Tehran, Iran), each containing 10 mg FLX 
hydrochloride,  were  accurately  weighed  individually  
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and finely powdered. Powdered sample containing 10 
mg FLX was weighed,  dissolved in 50–mL  ultrapure 
water and vigorously shaken on a vortex mixer for 30 
sec. The solution was then filtered and transferred into 
a 100–mL volumetric flask. The residue was washed in 
enough  ultrapure  water  and  the  solution  was  finally 
made up to the mark with water. Thus, a 100 µg/mL 
solution of FLX was obtained.  
Syrup:  2.5  mL  of  syrup  containing  20  mg  FLX/5mL 
was  transferred  into  a  100–mL  volumetric  flask  and 
made up to the mark with ultrapure water. Thus, a 100 
µg/mL solution of FLX was obtained. There isn't any 
need  for  filtration.  These  solutions  were  diluted 
quantitatively  to  yield  concentrations  in  the  range  of 
working  standard  solution  and  then  the  FLX  content 
was analyzed by the procedure proposed above. 
 
Procedure for urine sample 
Urine  samples  were  obtained  from  healthy  male 
volunteer  who  took  single  oral  dose  of  20  mg  FLX 
capsule. The samples were collected between 0–48 h, 
after administration and frozen at –20 °C until analysis. 
The  frozen  urine  samples  were  thawed  at  room 
temperature, centrifuged for 10 min at 4000 rpm and 
then  the  0.2  mL  of  the  supernatant  solutions  were 
subjected to the above mentioned procedure. 
 
Results and Discussion 
In  this  work,  DLLME  combined  with 
spectrofluorimetry  was  developed  and  optimized  for 
the  extraction  and  determination  of  FLX  in 
pharmaceutical  formulations  and  urine  samples.  To 
obtain  high  extraction  efficiency,  the  influence  of 
different factors affecting extraction conditions, such as 
kind  of  extraction  and  disperser  solvents  and  their 
volumes,  pH  of  sample  solution,  salt  effect,  sample 
volume, extraction time, centrifugation time and speed 
were  studied  and  optimized.  Figures  1  and  2  show 
excitation and emission spectra of FLX extracted from 
pharmaceutical  formulation  and  urine  sample  by 
DLLME, respectively, using the optimized conditions 
established  for  this  analysis.  The  excitation  and 
emission maxima were positioned at 234 ± 3 and 292 ± 
3 nm, respectively. 
 
 
Figure  1.  Excitation  (b)  and  emission  spectra  (a)  after  DLLME:  a1  &  b1:  reagent's  blank;  a2  &  b2:  FLX  solution  prepared  from 
pharmaceutical formulation (500 ng/mL); a3 & b3: sample ‘2’ spiked with FLX (100 ng/mL); a4 & b4: standard solution of FLX (750 
ng/mL). Other conditions have been mentioned in the text. 
 
 
Figure 2. Excitation (b) and emission spectra (a) after DLLME : a1 & b1: reagent's blank; a2 & b2: urine blank; a3 & b3: collected urine 
sample after administration of FLX to one volunteer; a4 & b4: sample ‘c’ spiked with FLX (250 ng/mL); (a5 & b5) standard solution of 
FLX (750 ng/mL). Other conditions have been mentioned in the text. 
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Effect of pH 
Obviously,  pH  was  the  key  parameter  for  sample 
solution,  affecting  the  states  of  analytes  and  the 
extraction  efficiency.  The  effect  of  sample  pH  was 
tested  in  the  pH  range  from  1  and  13.  As  shown  in 
Figure 3, the signal intensity of FLX improved with the 
increasing of pH from 1.0 to 10.0, and then remained 
approximately  constant  in  pH  from  10.0–13.0. 
According to the literature,
19 the pKa value of FLX is 
10.05. Hence, when the pH of the aqueous sample was 
higher  than  the  pKa  value  of  the  FLX,  the  analyte  is 
neutral  form  in  aqueous  solution  which  has  a  greater 
tendency  to  be  extracted  into  the  extraction  solvent. 
Accordingly,  the pH of  samples was adjusted  at  11.0 
with 1.0 mol/L ammonia buffer. 
 
Figure 3. Effect of pH on the analytical responses; FLX (500 
ng/mL), extraction with 800 µL of ethanol containing 100 µL of 
chloroform. 
 
Effect of the extraction and disperser solvent type 
Recovery  of  analytes  in  DLLME  depends  on  several 
factors.  Among  these  factors  the  main  role  can  be 
ascribed to the proper choice of the pair of two solvents: 
the  extraction  one  and  the  disperser  one.  Both  these 
solvents  have  to  meet  several  requirements.  The 
extraction  solvent  should  be  denser  than  water. 
Moreover it should demonstrate low solubility in water 
and potential for extracting analytes. Thus, chloroform, 
dichloromethane and carbon tetrachloride were studied 
as extraction solvents. The disperser solvent has to be 
miscible with both the water sample and the extraction 
solvent. It also has to enable formation of dispersion of 
the  extracting  solvent  in  the  water  sample.  Among 
different disperser solvents used in DLLME, methanol, 
ethanol, acetonitrile and acetone were studied. 
In  this  study,  all  combinations  of  dichloromethane, 
chloroform  and  carbon  tetrachloride  as  extraction 
solvents (60 µL) and methanol, ethanol, acetonitrile and 
acetone as dispersive solvents (500 µL) were tested and 
the  results  are  shown  in  Figure  4.  In  the  case  of 
dichloromethane  as  extraction  solvent,  a  two–phase 
system  was  not  observed  with  any  studied  disperser 
solvents.  This  is  probably  due  to  that  the  density  of 
dichloromethane  is  smaller  than  those  of  chloroform 
and  carbon  tetrachloride,  and  the  miscibility  of 
dichloromethane in the organic solvents are higher than 
those of chloroform and carbon tetrachloride. Thus it is 
not easy that dichloromethane deposited in the bottom 
of the test tube after spraying. The results revealed that 
with carbon tetrachloride and chloroform, a two–phase 
system was formed with all four dispersive solvents, but 
in the case of chloroform with ethanol more stable two–
phase systems and higher signals were observed. It is 
probably due to higher solubility of FLX in chloroform 
in  comparison  with  carbon  tetrachloride.  Thus 
chloroform and ethanol was selected as extraction and 
disperser  solvents,  respectively,  in  subsequent 
experiments. 
 
Figure 4. Effect of the type of extraction and disperser solvent 
on the analytical responses, EtOH: ethanol, MeOH: methanol, 
Ac:  acetone,  ACN:  Acetonitrile,  FLX  (500  ng/mL);  other 
conditions: 0.5 mL of 1.0 mol/L ammonia buffer; extraction with 
800  µL  of  disperser  solvent  containing  100  µL  of  extraction 
solvent. 
 
Effect of the extraction and disperser solvent volume 
The effect of the volume of the extraction solvent on the 
analytical  signals  was  investigated.  Experiments  were 
performed with different volumes of chloroform (in the 
range of 10–100 µL) as the extraction solvent by fixing 
the volume of the ethanol at 500 µL. Figure 5 indicates 
that the fluorescence intensity increased by increasing 
the  volume  of  the  chloroform  to  80  µL  and  then 
remained approximately constant by further increasing 
of  its  volume  to  100  µL.  At  higher  volumes  of 
extraction solvent, the ratio between the dispersive and 
extraction  solvent  decreased  which  probably  lowered 
the number of formed droplets and thereby decreased 
the  efficiency  of  extraction.  Based  on  these 
observations, a volume of 100 µL was used for further 
experiments. 
 
Figure  5.  Effect  of  the  extraction  solvent  volume  on  the 
analytical  signals;  other  conditions  have  been  mentioned 
in Figure 4.  
|   161 
DLLME and spectrofluorimetric determination of fluoxetine 
Advanced Pharmaceutical Bulletin, 2012, 2(2), 157-164  Copyright © 2012 by Tabriz University of Medical Sciences 
In order to examine the effect of the disperser solvent 
volume,  solutions  containing  different  volumes  of 
ethanol (in the range of 400–1800 µL) containing 100 
µL of chloroform were subjected to the same DLLME 
procedure. As shown in Figure 6, analytical responses 
reached to its maximum value at 800 µL of the ethanol. 
At  lower  volumes  of  the  disperser,  tiny  droplet 
formation  may  not  be  effective  thereby  lowering  the 
extraction  efficiency.  At  higher  volumes  of  the 
dispersive  solvent,  the  solubility  of  FLX  in  aqueous 
solution increases, thus lowering the partition of FLX 
into  chloroform  leading  to  a  decrease  in  efficiency. 
Thus this volume was used in other experiments.  
 
Figure 6. Effect of the disperser solvent volume on the analytical 
signals; other conditions have been mentioned in Figure 4. 
Effect of salt addition 
The effect of salt in this experiment was performed by 
adding  different  amounts  of  NaCl,  from  0%  to  20% 
(w/v),  and  other  experimental  conditions  were  kept 
constant.  With  the  increase  of  the  ionic  strength,  the 
signals were constant at first but decreased gradually by 
further increase of the salt concentration. Therefore, no 
addition  of  salt  was  employed  in  all  subsequent 
experiments. 
Effect of sample volume 
For  this  purpose  2.5,  5.0,  7.5  ,  10.0  and  12.5  mL 
aqueous solutions (containing 500 ng/mL of FLX) were 
selected  as  sample  size  and  the  DLLME  procedure 
using  ethanol  as  disperser  solvent  and  chloroform  as 
extraction  solvent  (200,  400,  600,  800  and  1000  µL, 
respectively)  was  performed.  Results  showed  that  by 
increasing  sample  volume  up  to  10  mL,  the 
fluorescence  intensity  increased.  This  is  evident  from 
the  fact  that  by  holding  sample  volume/dispersive 
solvent volume  ratio at  a  constant value  (12.5:1),  the 
volume  of  sedimented  phase  also  remains  almost 
constant. Therefore, by increasing sample volume and 
performing DLLME the concentration of analyte in the 
sedimented  phase  and  consequently,  the  enhancement 
factor (EF) are also increased. 
Effect of extraction time 
In DLLME, extraction time is defined as interval time 
between injecting the mixture of disperser solvent and 
extraction solvent, and before starting to centrifuge. The 
effect  of  extraction  time  was  examined  in  the  range 
0.25–20  min  with  constant  experimental  conditions. 
Results  (not  shown)  revealed  that  the  extraction  time 
had no effect on the response of the target analyte. This 
could  be  explained  by  the  fact  that  the  surface  area 
between the extraction solvent and the aqueous donor 
phase in DLLME is extremely large, thus the transfer of 
the  target  analyte  from  the  aqueous  phase  to  the 
extraction  solvent  phase  is  fast,  achieving  the 
equilibrium  state  quickly.  This  is  the  most  important 
advantage  of  DLLME  technique.  In  this  method,  the 
most time–consuming step is the centrifuging of sample 
solution in the extraction procedure, which is about 5 
min. 
Effect of other parameters 
The  effect  of  centrifugation  time  and  speed,  and  the 
type of final diluent solvent on the analytical responses 
were also investigated. Based on the obtained results, 5 
min, 3500 rpm and ethanol were selected as optimum 
centrifugation time and speed and final diluent solvent, 
respectively.  
Validation of the method  
Under the optimum experimental conditions, calibration 
graphs  were  obtained  by  DLLME  of  10.0  mL  of 
standard  solutions  containing  known  amount  of  the 
FLX and under the experimental conditions specified in 
the procedure. The calibration curve for the detection of 
FLX was linear over the concentration range of 10 to 
800 ng/mL. The corresponding fitted equation was FI = 
1.2281C–3.8067  with  r
2  =  0.9993,  where  FI  is  the 
fluorescence intensity and C is the FLX concentration 
in ng/mL. The LOD and the LOQ were determined by 
using the criterions LOD = 3Sb/m and LOQ = 10Sb/m, 
and  found  to  be  2.78  and  9.28  ng/mL,  respectively, 
where  Sb  is  the  standard  deviation  of  the  blank 
measurements  and  m  is  the  calibration  slope.  These 
values  are  below  the  usual  urinary  levels  in  patients 
under  daily  treatment.
23  The  RSD  obtained  for  the 
repetitive determinations of 60, 300 and 600 ng/mL of 
FLX  were  less  than  3.0%  (n  =  6).  The  inter–day 
repeatability  was  determined  by  analyzing  five 
replicates of 500 ng/mL of FLX and found to be 4.02%. 
A comparison of the main analytical characteristics of 
the  proposed  method  with  those  of  some  of  the  best 
previously reported methods are showed in Table 1. As 
can  be  seen,  proposed  method  provides  a  wider 
dynamic range and a lower LOD, and other analytical 
characteristics are comparable with reported techniques. 
The application of the method 
The method accuracy 
To investigate the accuracy of the proposed method, the 
solutions  prepared  from  FLX  formulations  as  well  as 
drug–free  urine  samples  were  spiked  at  three 
concentration  levels  of  200,  400  and  600  ng/mL  and 
extracted  under  the  optimized  conditions.  Each 
treatment was in triplicate and the results are shown in 
Table  2.  The  recoveries  for  the  commercial 
formulations and urine samples were in the range 96–
104 and 93–97%, respectively.    
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Table 1. Analytical characteristics of reported methods (including extraction techniques) for FLX determination 
Ex. & determination 
Method  Sample 
Concentration 
range (µg/mL) 
     (×10
2) 
Slope  r  RSD%  LOD 
(ng/mL) 
Mean 
recovery 
(%) 
Ref. 
MNPs–SPE/ fluorimetry  B.S  0.500–10.0  –  0.9983  1.40  20.0  80.0–104  1 
SPE–CE  B.S  0.100–20.0  6.55  0.9983  <3.10  10.0  89.0–99.0  2 
LLE–HPLC  B.S  0.500–5.00  2.25  0.9992  6.20–14.1  30.0  99.8–110  4 
LLE–Spectrophotometry  P.F  70.0–1000  0.020  0.9986  1.76  –  –  7 
Spectrophotometry & 
Spectrofluorimetry 
P.F 
≈ 
3.00–60.0 
0.350–5.00 
0.135 
0.579 
0.9997 
0.9992 
1.52 
3.37 
1.00×10
2 
10.0 
98.0–102 
97.5–100 
9 
≈ 
Spectrofluorimetry  P.F,B.S  0.400–10.0  0.776  0.9994  <1.00  9.60  98.0–104  10 
CZE  P.F  5.00–50.0  0.169  0.9998  1.50–2.20  1.00×10
2  99.3–102  11 
HPLC  P.F  0.100–1.20  0.006  0.9986  <0.800  3.00  98.0  12 
LPMEx.–HPLC  B.S  0.050–5.00  0.004  0.9999  5.40  LOQ=5.00  70.9  19 
SPME–HPLC  B.S  0.500–20.0  31.1  0.9990  <9.00  10.0  90.0–110  23 
SPE &LLE /GC–MS  B.S  0.050–75.0 & 
0.100–0.800  0.920  –  <5.00  1.00 &10.0  91.0–103  25 
DLLME–Spectrofluorimetry  P.F,B.S  0.100–8.00  0.228  0.9996  <3.00  2.78  93.0–104  This 
work 
CZE= Capillary zone electrophoresis; MEKC= Micellar electrokinetic capillary chromatography; Ex.=extraction; MNPs–SPE= Magnetic 
nanoparticles SPE; LPMEx.=Liquid phase microextraction; P.F= Pharmaceutical formulation; B.S= Biological sample. 
 
Table 2. Results of recoveries of spiked samples 
Sample  FLX added 
(ng/mL) 
†FLX found 
(ng/mL) 
Recovery 
(%) 
Capsule 
200  194 ± 5.28  97 
400  384 ± 9.93  96 
600  594 ± 11.8  99 
Syrup 
200  204 ± 4.36  102 
400  416 ± 8.62  104 
600  588 ± 12.3  98 
Human 
urine* 
200  186 ± 3.86  93 
400  384 ± 7.32  96 
600  582 ± 9.86  97 
*  A  0.2  mL  portion  of  urine  sample  was  used  for  recovery 
experiments. 
† Average of three determinations ± standard deviation. 
 
Typical extraction and emission spectra from standard 
solution  of  FLX,  real  solutions  prepared  from 
commercial  formulations  or  collected  urine  from  one 
volunteer  after  administration  of  FLX  and  the  latters 
spiked  with  FLX  are  shown  in  Figures  1  and  2, 
respectively.  As  can  be  seen  from  these  figures,  no 
additional picks due to interferences were observed at 
the  analytical  emission  wavelength.  Thus  the 
coincidence of emission spectra along with reasonable 
recoveries  demonstrates  that  the  commercial 
formulations  and  urine  matrixes  had  little  effect  on 
DLLME efficiency. 
On  the  other  hand,  a  calibration  curve  using  spiked 
urine sample was made. The comparison of the slopes 
of  standard  addition  and  routine  calibration  graphs 
showed that there was no significant difference between 
these  two  slopes  and  thus  there  were  no  significant 
matrix  effect.
2,37  Thus,  the  determination  of  FLX  in 
urine could be made by direct comparison with aqueous 
standard solution, at the same instrumental conditions.  
 
Application to the commercial formulation 
The proposed method was successfully applied to the 
analysis of FLX in its pharmaceutical dosage form (10 
mg per capsule and 20 mg/5mL syrup) and the results 
are summarized in Table 3. A comparison using t–test 
at 95% confidence interval demonstrates that there isn't 
any significant difference between achieved and labeled 
amounts.
38 
 
Table 3. Determination of FLX in pharmaceutical formulations 
Sample  *FLX etermined 
(mg) 
†Calculated 
t value 
20 mg capsule  9.62 ± 0.23  2.86 
20 mg/5mL syrup  19.7 ± 0.61  0.852 
* Average of three determinations ± standard deviation. 
† The tabulated t values at p = 0.05 is 4.3. 
38 
 
Application to the human urine 
A unique pharmacokinetic study was performed during 
two  days  by  analyzing  urine  samples  of  a  volunteer 
receiving  a  single  oral  dose  of  20  mg  FLX  capsule. 
Urine samples were collected for 0–48 h in 6 h intervals 
after  administration  and  these  collections  were 
monitored  for  FLX.  A  0.2  mL  portion  of  treated 
samples,  as  section  of  "Procedure  for  urine  sample", 
was  used  for  FLX  determination.  The  commutative 
FLX  amount  found  using  the  proposed  method  at 
different  interval  times,  are  shown  in  Figure  7.  The 
found  concentrations  were  in  the  range  of  51  to  106  
|   163 
DLLME and spectrofluorimetric determination of fluoxetine 
Advanced Pharmaceutical Bulletin, 2012, 2(2), 157-164  Copyright © 2012 by Tabriz University of Medical Sciences 
ng/mL witch were in accordance with values reported in 
the literature.
2 On the other hand, it must be mentioned 
that the proposed method can probably determine the 
total excreted FLX, since according to the literature,
19,20 
the FLX and its NFLX metabolite have same excitation 
and emission wavelengths. 
 
 
Figure 7. Time course of excreted FLX levels through urine. 
 
Conclusion 
A  new  DLLME  method  combined  with 
spectrofluorimetry has been presented for the extraction 
and  determination  of  FLX  in  pharmaceutical 
formulations and urine samples. In this method, sample 
preparation  time  as  well  as  consumption  of  toxic 
organic  solvents  was  minimized  without  affecting  the 
sensitivity of the method. In addition, it is avoided the 
need  of  employing  a  high  performance  separation 
instrument  for  the  treatment  of  urine  samples.  The 
proposed method gives a very rapid, simple, sensitive, 
wide  dynamic  range  and  low–cost  procedure  for  the 
determination  of  FLX.  The  method  can  be  further 
developed by combining DLLME with proper HPLC or 
GC  method  for  the  separation  and  determination  of 
FLX and its major metabolite. 
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